Log In Get Started
Press Releases August 27, 2026 09:01 AM

GRI Bio Featured in "Why Now" On-Demand Video Webcast

GRI Bio featured in 'Why Now' on-demand video webcast to highlight its innovative therapies.

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
GRI

GRI Bio, a biotechnology company listed on NASDAQ, announced its feature in the 'Why Now' on-demand video webcast, showcasing its work on developing therapies for inflammatory, fibrotic, and autoimmune diseases.

GRI Bio Featured in "Why Now" On-Demand Video Webcast
GRI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • GRI Bio is highlighted in a webcast focused on innovative biotechnology developments.
  • The company is advancing therapies targeting inflammatory, fibrotic, and autoimmune disorders.
  • The webcast aims to increase awareness and visibility of GRI Bio's therapeutic pipeline.

Video webcast now available here

LA JOLLA, CA, Aug. 27, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that it is featured in a

Risks

  • Market and clinical development risks inherent in biotechnology and pharmaceutical industries.
  • Uncertainty over how much the webcast exposure will translate into investor interest or new partnerships.
  • The competitive landscape for therapies in inflammatory and autoimmune diseases is intense and evolving.

More from Press Releases

Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 Sep 3, 2026 Fate Therapeutics to Participate in Fireside Chat at the 2026 Annual Cantor Global Healthcare Conference Sep 3, 2026 Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026 Sep 3, 2026 C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting Sep 3, 2026 LeonaBio to Participate in Cantor Global Healthcare Conference 2026 Sep 3, 2026